Increase of 1,25 dihydroxyvitamin D in sarcoidosis patients with renal dysfunction.


Journal

Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 11 10 2018
accepted: 27 05 2019
pubmed: 27 6 2019
medline: 20 2 2020
entrez: 27 6 2019
Statut: ppublish

Résumé

In sarcoidosis, renal involvement includes hypercalcemia-related nephrocalcinosis and granulomatous tubulointerstitial nephritis. Hypercalcemia is thought to be due to increased production of 1,25 dihydroxyvitamin D (1-25D), but 1-25D levels have not been evaluated in sarcoidosis patients with renal dysfunction. We enrolled 9 sarcoidosis patients who underwent renal biopsy, and compared the serum 1-25D concentration and eGFR with those in 428 non-sarcoidosis patients who had renal dysfunction (stage 2 or higher CKD with an estimated glomerular filtration rate < 90). Serum calcium and 1-25D levels were significantly higher in the sarcoidosis patients than in the non-sarcoidosis patients (p < 0.01 and p = 0.01, respectively). There was a positive correlation between 1-25D and eGFR in the patients without sarcoidosis (r = 0.693; p < 0.01). As the renal function of sarcoidosis patients was improved by steroid therapy, the serum 1-25D and adjusted serum calcium levels decreased to near the median values in non-sarcoidosis patients. On renal biopsy, CD68 staining was positive for tissue macrophages in all 8 patients who had tubulointerstitial nephritis (with or without typical granulomas), while Von Kossa staining showed calcification of tubules near or inside granulomas in 6 of these 8 patients. While tissue macrophages promote development of tubulointerstitial nephritis and 1-25D overproduction in renal sarcoidosis, hypercalcemia secondary to elevation of 1-25D may be related to renal calcification and granuloma formation.

Identifiants

pubmed: 31240503
doi: 10.1007/s10157-019-01760-3
pii: 10.1007/s10157-019-01760-3
doi:

Substances chimiques

Antigens, CD 0
Antigens, Differentiation, Myelomonocytic 0
CD68 antigen, human 0
Steroids 0
24,25-Dihydroxyvitamin D 3 40013-87-4
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1202-1210

Références

Am J Respir Crit Care Med. 1999 Aug;160(2):736-55
pubmed: 10430755
Clin Nephrol. 2006 Jun;65(6):449-52
pubmed: 16792143
J Bone Miner Res. 2007 Nov;22(11):1668-71
pubmed: 17645404
N Engl J Med. 2007 Nov 22;357(21):2153-65
pubmed: 18032765
Medicine (Baltimore). 2009 Mar;88(2):98-106
pubmed: 19282700
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
J Am Soc Nephrol. 2010 Sep;21(9):1427-35
pubmed: 20507943
Clin J Am Soc Nephrol. 2012 May;7(5):810-9
pubmed: 22362065
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Exp Nephrol. 2014 Feb;18(1):88-94
pubmed: 23722669
Sarcoidosis Vasc Diffuse Lung Dis. 2013 Aug 01;30(2):113-20
pubmed: 24071882
Intern Med. 2013;52(23):2639-44
pubmed: 24292755
BMJ Case Rep. 2014 Mar 24;2014:null
pubmed: 24663253
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 05;31(4):306-15
pubmed: 25591142
Am J Kidney Dis. 2016 Jul;68(1):e5-6
pubmed: 27343811
Endocr Rev. 2016 Oct;37(5):521-547
pubmed: 27588937

Auteurs

Naoya Toriu (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan. ntoriu@kuhp.kyoto-u.ac.jp.
Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan. ntoriu@kuhp.kyoto-u.ac.jp.

Keiichi Sumida (K)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masahiko Oguro (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Yoichi Oshima (Y)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Hiroki Mizuno (H)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Eiko Hasegawa (E)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Tatsuya Suwabe (T)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masahiro Kawada (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Toshiharu Ueno (T)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Noriko Hayami (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Akinari Sekine (A)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Rikako Hiramatsu (R)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Masayuki Yamanouchi (M)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Junichi Hoshino (J)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Naoki Sawa (N)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.

Kenmei Takaichi (K)

Nephrology Center, Toranomon Hospital, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Kenichi Ohashi (K)

Department of Pathology, Toranomon Hospital, Tokyo, Japan.
Department of Pathology, Yokohama City Hospital, Kanagawa, Japan.

Keiichi Kinowaki (K)

Department of Pathology, Toranomon Hospital, Tokyo, Japan.

Takeshi Fujii (T)

Department of Pathology, Toranomon Hospital, Tokyo, Japan.

Ryosuke Date (R)

Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital, Tokyo, Japan. ubara@toranomon.gr.jp.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan. ubara@toranomon.gr.jp.
Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Takatsu, Kawasaki, 212-0015, Kanagawa, Japan. ubara@toranomon.gr.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH